Bank of Nova Scotia
PFE icon

Bank of Nova Scotia’s Pfizer PFE Stock Holding History

Bank of Nova Scotia’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,000
Closed -$159K – 1095
2024
Q4 		$159K Buy
+6,000
New +$163K ﹤0.01% 965

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Bank of Nova Scotia's PFE Position: Q1 2026 in Review

Bank of Nova Scotia increased its Pfizer (PFE) stake by 58% in Q1 2026, buying an estimated $49.7M and bringing the position to 5,108,792 shares worth $143M. The position accounts for 0.25% of the portfolio, ranked #73.

Bank of Nova Scotia first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $474M in Q4 2021. 2,946 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Bank of Nova Scotia held 5,108,792 shares of Pfizer worth $143M as of Q1 2026.
  • Bank of Nova Scotia bought 1,865,170 Pfizer shares in Q1 2026, an estimated $49.7M.
  • Pfizer made up 0.25% of Bank of Nova Scotia's portfolio in Q1 2026, its #73 holding.
  • Bank of Nova Scotia first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Bank of Nova Scotia's Pfizer position peaked at $474M in Q4 2021.
  • 2,946 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.